Annual accounts receivable:
$660.53M+$26.83M(+4.23%)Summary
- As of today (July 1, 2025), BMRN annual accounts receivable is $660.53 million, with the most recent change of +$26.83 million (+4.23%) on December 31, 2024.
- During the last 3 years, BMRN annual accounts receivable has risen by +$287.14 million (+76.90%).
- BMRN annual accounts receivable is now at all-time high.
Performance
BMRN Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$739.18M+$78.64M(+11.91%)Summary
- As of today (July 1, 2025), BMRN quarterly accounts receivable is $739.18 million, with the most recent change of +$78.64 million (+11.91%) on March 31, 2025.
- Over the past year, BMRN quarterly accounts receivable has increased by +$102.01 million (+16.01%).
- BMRN quarterly accounts receivable is now -4.93% below its all-time high of $777.55 million, reached on September 30, 2024.
Performance
BMRN Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
BMRN Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.2% | +16.0% |
| 3 y3 years | +76.9% | +71.8% |
| 5 y5 years | +75.0% | +86.5% |
BMRN Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +76.9% | -4.9% | +76.2% |
| 5 y | 5-year | at high | +76.9% | -4.9% | +98.0% |
| alltime | all time | at high | >+9999.0% | -4.9% | >+9999.0% |
BMRN Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $739.18M(+11.9%) |
| Dec 2024 | $660.53M(+4.2%) | $660.53M(-15.0%) |
| Sep 2024 | - | $777.55M(+12.5%) |
| Jun 2024 | - | $691.23M(+8.5%) |
| Mar 2024 | - | $637.16M(+0.5%) |
| Dec 2023 | $633.70M(+37.4%) | $633.70M(+10.7%) |
| Sep 2023 | - | $572.50M(-6.2%) |
| Jun 2023 | - | $610.22M(+2.1%) |
| Mar 2023 | - | $597.91M(+29.6%) |
| Dec 2022 | $461.32M(+23.5%) | $461.32M(+9.9%) |
| Sep 2022 | - | $419.62M(-10.1%) |
| Jun 2022 | - | $466.51M(+8.5%) |
| Mar 2022 | - | $430.15M(+15.2%) |
| Dec 2021 | $373.40M(-16.7%) | $373.40M(-0.4%) |
| Sep 2021 | - | $374.94M(-11.7%) |
| Jun 2021 | - | $424.42M(+7.2%) |
| Mar 2021 | - | $396.10M(-11.7%) |
| Dec 2020 | $448.35M(+18.8%) | $448.35M(+8.9%) |
| Sep 2020 | - | $411.71M(+8.0%) |
| Jun 2020 | - | $381.21M(-3.8%) |
| Mar 2020 | - | $396.38M(+5.0%) |
| Dec 2019 | $377.40M(+10.1%) | $377.40M(-6.3%) |
| Sep 2019 | - | $402.97M(+6.8%) |
| Jun 2019 | - | $377.15M(-4.1%) |
| Mar 2019 | - | $393.43M(+14.8%) |
| Dec 2018 | $342.63M(+31.1%) | $342.63M(-10.9%) |
| Sep 2018 | - | $384.34M(+5.7%) |
| Jun 2018 | - | $363.57M(+14.2%) |
| Mar 2018 | - | $318.39M(+21.8%) |
| Dec 2017 | $261.37M(+21.4%) | $261.37M(+3.8%) |
| Sep 2017 | - | $251.89M(+5.7%) |
| Jun 2017 | - | $238.34M(+3.5%) |
| Mar 2017 | - | $230.25M(+7.0%) |
| Dec 2016 | $215.28M(+30.5%) | $215.28M(-0.3%) |
| Sep 2016 | - | $215.89M(+0.8%) |
| Jun 2016 | - | $214.16M(+18.5%) |
| Mar 2016 | - | $180.75M(+9.6%) |
| Dec 2015 | $164.96M(+14.2%) | $164.96M(+10.7%) |
| Sep 2015 | - | $148.95M(-20.0%) |
| Jun 2015 | - | $186.08M(+5.9%) |
| Mar 2015 | - | $175.74M(+21.6%) |
| Dec 2014 | $144.47M(+22.6%) | $144.47M(+19.0%) |
| Sep 2014 | - | $121.39M(-0.7%) |
| Jun 2014 | - | $122.28M(+10.7%) |
| Mar 2014 | - | $110.46M(-6.2%) |
| Dec 2013 | $117.82M | $117.82M(-5.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $124.75M(+8.4%) |
| Jun 2013 | - | $115.06M(-4.4%) |
| Mar 2013 | - | $120.34M(+10.3%) |
| Dec 2012 | $109.07M(+4.0%) | $109.07M(-7.0%) |
| Sep 2012 | - | $117.29M(+16.4%) |
| Jun 2012 | - | $100.75M(-4.8%) |
| Mar 2012 | - | $105.83M(+0.9%) |
| Dec 2011 | $104.84M(+21.1%) | $104.84M(-2.1%) |
| Sep 2011 | - | $107.06M(+0.4%) |
| Jun 2011 | - | $106.61M(+0.4%) |
| Mar 2011 | - | $106.20M(+22.7%) |
| Dec 2010 | $86.58M(+17.7%) | $86.58M(+10.0%) |
| Sep 2010 | - | $78.73M(+1.4%) |
| Jun 2010 | - | $77.68M(-6.0%) |
| Mar 2010 | - | $82.61M(+12.3%) |
| Dec 2009 | $73.54M(+35.4%) | $73.54M(+7.5%) |
| Sep 2009 | - | $68.38M(-5.8%) |
| Jun 2009 | - | $72.58M(+18.3%) |
| Mar 2009 | - | $61.35M(+13.0%) |
| Dec 2008 | $54.30M(+219.9%) | $54.30M(+6.2%) |
| Sep 2008 | - | $51.13M(-2.0%) |
| Jun 2008 | - | $52.16M(+10.4%) |
| Mar 2008 | - | $47.25M(+178.4%) |
| Dec 2007 | $16.98M(+15.7%) | $16.98M(+6.3%) |
| Sep 2007 | - | $15.97M(+0.4%) |
| Jun 2007 | - | $15.90M(+9.5%) |
| Mar 2007 | - | $14.53M(-1.0%) |
| Dec 2006 | $14.67M(+150.3%) | $14.67M(+12.8%) |
| Sep 2006 | - | $13.00M(+18.8%) |
| Jun 2006 | - | $10.95M(+46.1%) |
| Mar 2006 | - | $7.49M(+27.9%) |
| Dec 2005 | $5.86M(+44.8%) | $5.86M(+10.0%) |
| Sep 2005 | - | $5.33M(+85.6%) |
| Jun 2005 | - | $2.87M(+56.8%) |
| Mar 2005 | - | $1.83M(-54.8%) |
| Dec 2004 | $4.05M(+30.7%) | $4.05M(+3300.8%) |
| Sep 2004 | - | $119.00K(-97.4%) |
| Jun 2004 | - | $4.61M(+97.8%) |
| Sep 2002 | - | $2.33M(+9.2%) |
| Jun 2002 | - | $2.13M(-63.7%) |
| Mar 2002 | - | $5.89M(+90.2%) |
| Dec 2001 | $3.10M(+72.1%) | $3.10M(+210.8%) |
| Sep 2001 | - | $996.00K(+37.0%) |
| Jun 2001 | - | $727.00K(-3.6%) |
| Mar 2001 | - | $754.00K(-58.1%) |
| Dec 2000 | $1.80M(-27.0%) | $1.80M(-27.0%) |
| Dec 1999 | $2.47M | $2.47M |
FAQ
- What is BioMarin Pharmaceutical annual accounts receivable?
- What is the all time high annual accounts receivable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual accounts receivable year-on-year change?
- What is BioMarin Pharmaceutical quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly accounts receivable year-on-year change?
What is BioMarin Pharmaceutical annual accounts receivable?
The current annual accounts receivable of BMRN is $660.53M
What is the all time high annual accounts receivable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual accounts receivable is $660.53M
What is BioMarin Pharmaceutical annual accounts receivable year-on-year change?
Over the past year, BMRN annual accounts receivable has changed by +$26.83M (+4.23%)
What is BioMarin Pharmaceutical quarterly accounts receivable?
The current quarterly accounts receivable of BMRN is $739.18M
What is the all time high quarterly accounts receivable for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly accounts receivable is $777.55M
What is BioMarin Pharmaceutical quarterly accounts receivable year-on-year change?
Over the past year, BMRN quarterly accounts receivable has changed by +$102.01M (+16.01%)